ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): Study protocol for a Phase Ib/II open-label non-randomised clinical trial
Katy Mercer*, Andrew Davies, Sharon Barrans, Cathy Burton, Joshua Caddy, Fay Chinnery, Laura Day, Diana Fernando, Kirit Ardeshna, Graham Collins, John Radford, Simon Rule, Andrew McMillan, Peter Johnson, Gareth Griffiths
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): Study protocol for a Phase Ib/II open-label non-randomised clinical trial'. Together they form a unique fingerprint.